NEORANKER
DEAD

Serial Number

98292345

Owner

ACHILLES THERAPEUTICS UK LIMITED

Attorney

Rebecca Liebowitz

Filing Date

Nov 30, 2023

Add to watchlist:

No watchlists yet
View on USPTO

NEORANKER Trademark

Serial Number: 98292345

NEORANKER is a trademark filed by ACHILLES THERAPEUTICS UK LIMITED on November 30, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

ACHILLES THERAPEUTICS UK LIMITED (7 trademarks)

245 HAMMERSMITH ROAD
LONDON W6 8PW , GB

Entity Type: 24

Trademark Details

Filing Date

November 30, 2023

Registration Date

Not Registered

Goods & Services

Custom manufacture of therapeutic drugs; namely custom manufacture of cell therapies and cancer therapies

Bioinformatics software; computer software platforms

Medical and veterinary preparations for therapeutic purposes; preparations for cancer therapy; antibodies; vaccines; preparations for cell therapy; preparations for modifying human or animal cells for medical or therapeutic purposes; preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes

Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies

Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research into cancer evolution and clonal architecture; scientific research in human and animal cell therapy; scientific research into vaccines; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; Software as a service; providing a bioinformatics platform for manufacturing therapeutics; providing a bioinformatics platform for identifying neoantigens

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 23, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 23, 2025 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 30, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 30, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 5, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 28, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2024 NWOS
NEW APPLICATION ENTERED
Nov 30, 2023 NWAP